IPG1094

· Nanjing Immunophage Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IPG1094, covering 2025-09-24 to 2025-09-24. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients [Phase 1, Phase 2]